A worldwide collaboration involving BCI’s Prof Thomas Powles, Centre for Experimental Cancer Medicine, has revealed mechanisms involved in the development of response and resistance to an immune checkpoint inhibitor in metastatic urothelial cancer. The findings may highlight ways to improve the efficacy of this treatment in the hope of achieving long-term remission for patients.
Patients with an aggressive form of leukaemia, currently ineligible for any type of targeted therapy, may in fact benefit from new drugs, according to new research by Barts Cancer Institute at Queen Mary University of London.
